Pfizer gene therapy trial - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

VA Tech Wabag (NSE: WABAG) wins order from CMWSSB for 45 MLD Chennai TTRO plant

Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway

Representative image of enterprise cloud cybersecurity infrastructure illustrating how Accenture plc and Google Cloud are strengthening cloud security defenses against AI-driven cyber threats and multi-cloud security risks.

How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Pfizer Inc.'s CIFFREO study on gene therapy for Duchenne muscular dystrophy did not meet its primary motor function improvement endpoint.

Read More

2 minute read

Pharma Industry News

Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint

Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study…

byPallavi Madhiraju

June 14, 2024

web analytics